{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:44Z","timestamp":1790959364619,"version":"4.1.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2017,6,30]]},"DOI":"10.3233\/jhd-170245","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T11:05:58Z","timestamp":1498820758000},"page":"157-163","source":"Crossref","is-referenced-by-count":74,"title":["Fifteen Years of Clinical Trials in\u00a0Huntington\u2019s Disease: A Very Low Clinical\u00a0Drug Development Success Rate"],"prefix":"10.1177","volume":"6","author":[{"given":"Andr\u00e9 M.","family":"Travessa","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe B.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal"},{"name":"Huntington\u2019s Disease Centre, Institute of Neurology, University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal"},{"name":"CNS \u2013 Campus Neurol\u00f3gico S\u00e9nior, Torres Vedras, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-170245_ref1","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.3233\/JHD-170245_ref2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JHD-170245_ref3","doi-asserted-by":"crossref","unstructured":"Rodrigues FB , Abreu D , Dam\u00e1sio J , Goncalves N , Correia-Guedes L , Coelho M , et al. Survival, mortality, causes and places of death in a European Huntington\u2019s Disease Prospective Cohort. Mov Disord Clin Pract. 2017. doi: 10.1002\/mdc3.12502","DOI":"10.1002\/mdc3.12502"},{"issue":"9","key":"10.3233\/JHD-170245_ref4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington\u2019s disease: A systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-170245_ref5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.3233\/JHD-170245_ref6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","article-title":"Huntington\u2019s disease: An update of therapeutic strategies","volume":"556","author":"Kumar","year":"2015","journal-title":"Gene"},{"issue":"3","key":"10.3233\/JHD-170245_ref10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","article-title":"Update on Huntington\u2019s disease: Advances in care and emerging therapeutic options","volume":"21","author":"Zielonka","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-170245_ref11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1745-6215-15-428","article-title":"Characteristics of clinical trial websites: Information distribution between ClinicalTrials.gov and 13 primary registries in the WHO registry network","volume":"15","author":"Ogino","year":"2014","journal-title":"Trials"},{"issue":"9","key":"10.3233\/JHD-170245_ref12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database \u2013 update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.3233\/JHD-170245_ref14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13063-016-1310-8","article-title":"When are clinical trials registered? An analysis of prospective versus retrospective registration","volume":"17","author":"Harriman","year":"2016","journal-title":"Trials"},{"issue":"3","key":"10.3233\/JHD-170245_ref15","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.3233\/JHD-170245_ref16","first-page":"CD006455","article-title":"Therapeutic interventions for disease progression in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JHD-170245_ref17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3325\/cmj.2008.5.582","article-title":"Registration of clinical trials still moving ahead\u2013September update to Uniform Requirements for Manuscripts Submitted to Biomedical Journals","volume":"49","author":"Marusi\u0107","year":"2008","journal-title":"Croat Med J"},{"key":"10.3233\/JHD-170245_ref18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/erd.09.64","article-title":"Why do some promising brain-stimulation devices fail the next steps of clinical development?","volume":"7","author":"Edelmuth","year":"2010","journal-title":"Expert Rev Med Devices"},{"issue":"2","key":"10.3233\/JHD-170245_ref19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.nurt.2008.02.002","article-title":"Noninvasive brain stimulation for Parkinson\u2019s disease and dystonia","volume":"5","author":"Wu","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JHD-170245_ref20","first-page":"687909","article-title":"Effect of transcranial brain stimulation for the treatment of Alzheimer disease: A review","author":"Nardone","year":"2012","journal-title":"Int J Alzheimers Dis"},{"issue":"4","key":"10.3233\/JHD-170245_ref21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.3233\/JHD-170245_ref22","first-page":"1","article-title":"Clinical success rates for new cancer drugs double while more enter testing","volume":"15","author":"DiMasi","year":"2013","journal-title":"Tufts Center Study Drug Dev"},{"issue":"1","key":"10.3233\/JHD-170245_ref23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.3233\/JHD-170245_ref24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.3233\/JHD-170245_ref25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: Is it really 802 million dollars?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.3233\/JHD-170245_ref26","doi-asserted-by":"crossref","first-page":"g3727","DOI":"10.1136\/bmj.g3727","article-title":"What are the four phases of clinical research trials?","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ"},{"key":"10.3233\/JHD-170245_ref27","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.3233\/JHD-170245_ref28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.18632\/oncoscience.173","article-title":"Challenges and perspective of drug repurposing strategies in early phase clinical trials","volume":"2","author":"Kato","year":"2015","journal-title":"Oncoscience"},{"issue":"2","key":"10.3233\/JHD-170245_ref29","doi-asserted-by":"crossref","first-page":"e14701","DOI":"10.1371\/journal.pone.0014701","article-title":"The quality of registration of clinical trials","volume":"6","author":"Viergever","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JHD-170245_ref30","doi-asserted-by":"crossref","first-page":"e84727","DOI":"10.1371\/journal.pone.0084727","article-title":"The quality of registration of clinical trials: Still a problem","volume":"9","author":"Viergever","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JHD-170245_ref31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13063-016-1310-8","article-title":"When are clinical trials registered? An analysis of prospective versus retrospective registration","volume":"15","author":"Harriman","year":"2016","journal-title":"Trials"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:17Z","timestamp":1777453037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":27,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170245","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]}}}